Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Vaccines

  Free Subscription


Articles published in PLoS Med

Retrieve available abstracts of 14 articles:
HTML format



Single Articles


    June 2025
  1. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
    Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
    PLoS Med. 2025;22:e1004631.
    PubMed     Abstract available


    April 2025

  2. Correction: Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
    PLoS Med. 2025;22:e1004605.
    PubMed     Abstract available


    February 2025
  3. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004521.
    PubMed     Abstract available


  4. INGABIRE R, Nyombayire J, Mazzei A, Mazarati JB, et al
    Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
    PLoS Med. 2025;22:e1004508.
    PubMed     Abstract available


  5. GRAIS RF, Neuzil KM, Rees H, Toscano CM, et al
    Protecting mother and baby: Learnings from an Ebola vaccination campaign on the evolving landscape of vaccines and pregnancy.
    PLoS Med. 2025;22:e1004530.
    PubMed     Abstract available


  6. GUTTIERES D, Diepvens C, Grais RF, Kiarie J, et al
    Charting a novel path towards Ebola virus disease preparedness: Considerations for preventive vaccination.
    PLoS Med. 2025;22:e1004543.
    PubMed     Abstract available


    January 2025
  7. SEIDLEIN LV
    Roll out and prospects of the malaria vaccine R21/Matrix-M.
    PLoS Med. 2025;22:e1004515.
    PubMed     Abstract available


  8. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Correction: Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004573.
    PubMed     Abstract available


    October 2024
  9. MUNDAY JD, Atkins KE, Klinkenberg D, Meurs M, et al
    Estimating the risk and spatial spread of measles in populations with high MMR uptake: Using school-household networks to understand the 2013 to 2014 outbreak in the Netherlands.
    PLoS Med. 2024;21:e1004466.
    PubMed     Abstract available


    September 2024
  10. INIZAN C, Courtot A, Sturmach C, Griffon AF, et al
    Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.
    PLoS Med. 2024;21:e1004397.
    PubMed     Abstract available


    June 2024
  11. PEREZ CHACON G, Estcourt MJ, Totterdell J, Marsh JA, et al
    Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
    PLoS Med. 2024;21:e1004414.
    PubMed     Abstract available


  12. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
    Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
    PLoS Med. 2024;21:e1004375.
    PubMed     Abstract available


    April 2024
  13. JUNG SM, Loo SL, Howerton E, Contamin L, et al
    Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
    PLoS Med. 2024;21:e1004387.
    PubMed     Abstract available


    March 2024
  14. MOODIE Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, et al
    Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    PLoS Med. 2024;21:e1004360.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.